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Abstract
Background: Rheumatic heart disease (RHD), caused by acute rheumatic fever (ARF), is a major health problem in
Australian Aboriginal communities. Progress in controlling RHD requires improvements in the delivery of secondary
prophylaxis, which comprises regular, long-term injections of penicillin for people with ARF/RHD.
Methods/Design: This trial aims to improve uptake of secondary prophylaxis among Aboriginal people with
ARF/RHD to reduce progression or worsening of RHD. This is a stepped-wedge, randomised trial in consenting
communities in Australia’s Northern Territory. Pairs of randomly-chosen clinics from among those consenting
enter the study at 3-monthly steps. The intervention to which clinics are randomised comprises a multi-faceted
systems-based package, in which clinics are supported to develop and implement strategies to improve penicillin
delivery, aligned with elements of the Chronic Care Model. Continuous quality improvement processes will be used,
including 3-monthly feedback to clinic staff of adherence rates of their ARF/RHD clients.
The primary outcome is the proportion of people with ARF/RHD receiving ≥80 % of scheduled penicillin injections
over a minimum 12-month period. The sample size of 300 ARF/RHD clients across five community clusters will power
the study to detect a 20 % increase in the proportion of individuals achieving this target, from a worrying low baseline
of 20 %, to 40 %. Secondary outcomes pertaining to other measures of adherence will be assessed. Within the
randomised trial design, a mixed-methods evaluation will be embedded to evaluate the efficiency, effectiveness,
impact and relevance, sustainability, process and fidelity, and performance of the intervention. The evaluation will
establish any causal link between outcomes and the intervention. The planned study duration is from 2013 to 2016.
Discussion: Continuous quality improvement has a strong track record in Australia’s Northern Territory, and its use has
resulted in modest benefits in a pilot, non-randomised ARF/RHD study. If successful, this new intervention using
the Chronic Care Model as a scaffold and evaluated using a well-developed theory-based framework, will provide
a practical and transferable approach to ARF/RHD control.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000223730. Date registered: 25
February 2013
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Background
Acute rheumatic fever (ARF) and its sequel, rheumatic
heart disease (RHD), remain important causes of morbidity
and mortality in areas of socioeconomic deprivation. Rates
in Australia’s remote-dwelling Aboriginal populations are
amongst the highest reported globally; the rate in school-
aged Aboriginal children in Australia’s Northern Territory
(NT) in 2005–2009 was estimated at 150–380 per 100,000
[1–3]. Numerous steps have been taken to attempt to
reduce the burden of ARF/RHD in Australia. In the NT,
this has included: making ARF a notifiable disease; devel-
oping and funding a register and control programme to
coordinate patient care; developing freely available patient
resources, staff training modules and management guide-
lines [2]; developing a new smartphone application for
ARF diagnosis to help health care staff unfamiliar with
the disease [4]; and other initiatives. However, the bar-
riers to ARF/RHD prevention remain prevalent and are
multi-factorial.
ARF is a preventable disease caused by an abnormal
host immune response that can develop after infection with
group A streptococcus, a common cause of pharyngitis and
skin sores. Children aged 5–14 years are most at risk. In re-
mote NT Aboriginal communities, exposure to pathogenic
group A streptococcal strains is frequent, but only a small
proportion of individuals develop the autoimmune re-
sponse causing ARF. Recurrent ARF episodes cause
cumulative heart valve damage, leading to RHD and its
serious complications: heart failure, atrial fibrillation,
requirement for major cardiac surgery for valvular repair,
anticoagulation, thrombotic and haemorrhagic complica-
tions including stroke, endocarditis and premature mortal-
ity. A recent NT study demonstrated that after a first ARF
diagnosis, 61 % of people developed RHD within 10 years,
and of those nearly 30 % progress to heart failure within
5 years [5]. Given the young age of disease onset the
morbidity burden and cost to society is very high.
Secondary prophylaxis
Strategies for ARF prevention exist at the primordial,
primary, secondary and tertiary levels [3]. Secondary pre-
vention is the strategy with the best-proven efficacy and
cost-effectiveness [6, 7]. This comprises regular antibiotic
prophylaxis to prevent further streptococcal infections, and
hence ARF recurrences, among individuals after their first
ARF diagnosis. The standard recommended antibiotic
regimen is 4-weekly intramuscular injections of benzathine
(long-acting) penicillin G, for 10 years after the last ARF
episode or until age 21, whichever is longer. Longer dura-
tions are required in people with moderate to severe RHD.
This strategy significantly reduces ARF recurrence rates
compared with placebo [8] or oral penicillin [7]. It forms
the cornerstone of the World Health Organisation’s RHD
prevention strategy globally [9], and the Australian guide-
lines locally [2].
It is believed that the most effective way to govern deliv-
ery of secondary prophylaxis, as well as other elements of
ARF/RHD clinical care, is via register-based control pro-
grammes [10]. The NT RHD Control Programme and
Register were established in the north of the NT in 1997.
A key challenge exists in improving adherence to
secondary prophylaxis. Individuals should ideally receive
every scheduled injections to ensure continual protection
from streptococcal infection and subsequent ARF epi-
sodes. A more achievable target is ≥80 % of scheduled
injections [2], yet the proportion of clients with ARF/
RHD achieving this target in the NT in 2009 was only
23 % [11].
Adherence
Adherence is a major theme in the discussion of chronic
disease management in Australian Indigenous people [12].
Determinants of adherence can be understood within
the key domains of socioeconomic factors, health systems,
medications including adverse effects, clients and the
medical condition itself [13]. Adherence to ARF/RHD
secondary prophylaxis, a directly-observed, health care
provider-administered injection, includes unique additional
challenges: the treatment is an often painful needle-prick;
health care staff turnover in remote clinics is exceptionally
high, and their knowledge of ARF/RHD is often poor; pa-
tient populations are young and mobile; health literacy
tends to be low; and furthermore, patient traditional
knowledge, world view and expectations of health care dif-
fer from what is offered by traditional Western medical
models [14–16]. Two small studies in northern Australia
found that adherence among Aboriginal clients with
ARF/RHD appeared unrelated to their health literacy
or to fear of injections, but instead to their relationship
with primary care staff and the presence of active recall
systems [14, 15].
At the health centre level, important determinants
of adherence identified in other studies include a cul-
ture free from institutional racism, with a degree of
community control, strong leadership and opportunities
for building the capacity of local workforce [17, 18]. A
Cochrane review of the international literature on ad-
herence support initiatives found only modest benefits,
even from quite labour-intensive strategies [19]. Such
findings set a challenge for studies such as ours. How-
ever, adherence to an administered injection provides
an opportunity for creative, multi-dimensional health-
centre-based strategies, and the existing evidence base
for improving health service delivery in our setting (see
below) provides optimism that a carefully planned strategy
can be successful.
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The chronic care model
The logical approach to improving secondary prophylaxis
uptake in the NT setting would comprise an intervention
targeting the recognised challenges to secondary prophy-
laxis adherence, with a key focus on health service deliv-
ery. We have selected the Chronic Care Model (CCM) as
a scaffold for implementing an intervention package at
participating health centres. The CCM is a comprehensive
system approach for chronic disease management, in-
corporating six domains: health systems, delivery system
design, decision support, clinical information systems,
self-management support and community linkages [20].
The CCM is appropriate since although individual ARF
episodes are by definition acute, the required management
(long-term regular secondary prophylaxis and engagement
with health services) is synonymous with chronic disease
management, and the long-term complication, RHD,
is chronic. The advantage of the CCM is that it is a
‘whole-system’ model targeting both the client and the
health service. It is also the current framework for the
NT Chronic Disease Strategy and, therefore, situates the
study well within current practices; this should enhance
local transferability if the trial is successful [21].
Continuous quality improvement processes
One approach which has been successfully adopted in
the NT to achieve systems change at health clinics has
been systematic continuous quality improvement (CQI)
activities [22]. CQI strategies engaging primary health
staff have been shown to improve health outcomes in re-
mote clinics in the NT [23]. Health systems improvements
providing a ‘comprehensive-care programme’ were shown
to reduce ARF rates in the USA as long as four decades
ago [24], and reductions in ARF burdens have been
achieved in Cuba and the Caribbean with programmes
combining community education strategies with health care
improvements (e.g. development of a register, education for
health staff) [25, 26].
Specifically, regarding ARF/RHD in the NT, we have
shown that application of a CQI process over 3 years at
six remote clinics in the NT led to small but statistically
significant improvements in some proximal outcome
measures for ARF/RHD patients [11]. Tools used included
an audit tool allowing clinics to monitor their delivery of
services to ARF/RHD clients, and a ‘systems assessment
tool’ addressing systemic impediments to RHD service
delivery. These tools are contained within the National
Centre for Quality Improvement in Indigenous Primary
Health Care (‘One21seventy’) package [27]. Our study
showed substantial variability between sites in their de-
livery of RHD services, and in the strategies they used
to promote RHD service delivery. Factors associated
with performance in these clinics are listed in Table 1
(listed in order of amenability to change). Many could
potentially be addressed using existing resources.
Another recent study in NT remote clinics implemented
a Chronic Conditions Management Model, comprising
decision support for health care staff and provision of
simple, coloured (‘traffic light’) reports to monitor the
alignment of a clinic’s performance with goals. This was
associated with improved patient outcomes [28]. The au-
thors concluded that even in Australia’s most challenging
primary health care contexts, improvements were achiev-
able by identifying clear goals, and providing staff with
support and feedback including reports generated from
the clinic’s own data [28]. CQI processes, under the CCM
domain of clinical information systems, will be integrated
into our study’s intervention package; this will include
3-monthly feedback to clinic staff of adherence rates of
their ARF/RHD clients.
Objectives
Given the major burden posed by ARF/RHD for Abori-
ginal people in the NT, the proven benefit of secondary
prevention with regular penicillin injections, but the
challenges of delivering secondary prevention effectively,
we therefore aim to improve the uptake of secondary
Table 1 Summary of factors influencing performance of six remote Northern Territory health centres in delivering services to clients
with acute rheumatic fever/rheumatic heart disease (ARF/RHD)
Determinants of relatively good performance Determinants of relatively poor performance
• Clear allocation of responsibility for rheumatic heart disease (RHD)
care among health centre staff
• Good regional management – commitment to continuous quality
improvement (CQI), resourcing for CQI
• Effective feedback and management action in response to feedback
from CQI process
• Good Aboriginal health worker involvement in health centre operations
• Good outreach arrangements – including drivers, Aboriginal health
workers
• Public health-oriented chronic disease support from regional level to
health centres
• Staff stability and continuity, including availability of experienced
general practitioner
• Client flows in health centres do not direct ARF/RHD clients to staff
responsible for RHD care
• Lack of clear allocation of responsibility for RHD care
• Lack of effective outreach services
• Changes and inefficiencies in clinical information systems
• Lack of regular/stable staffing, including general practitioner service
• Health centre management turnover, unstable management structure
• Larger number of clients, complexities of urban environment
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prophylaxis among people with ARF/RHD. The predicted
consequences of improved uptake are reduced rates of
recurrent ARF episodes and mitigation of RHD devel-
opment or progression. The primary objective is to test
whether an intervention to optimise health systems can
improve adherence to secondary prophylaxis for RHD.
Objectives of the mixed-methods evaluation are to test
efficiency, effectiveness, impact and relevance, sustain-




This is a stepped-wedge, community randomised trial
with an open cohort design. Key characteristics of the
trial are shown in Table 2 and Fig. 1. A stepped-wedge
trial is a type of cluster randomised trial in which ‘clus-
ters receive the intervention at different time points, the
order in which they receive it is randomised, and data
are collected from clusters over time’ [29]. The open co-
hort means that individuals may leave during the trial
(no longer require ARF/RHD secondary prophylaxis, die
or move to a non-study community), or may become
eligible during the trial (receive a new diagnosis of
ARF/RHD requiring secondary prophylaxis). Steps of
3 months’ duration were chosen to provide a feasible
total study duration whilst providing adequate time for
project staff to accomplish intensive visits for incoming
clusters. A lag time of 3 months has been anticipated
between commencing the intervention and onset of a
perceivable effect, hence data collection for quantitative
measures during the intervention period will commence
3 months after the onset of the intensive phase for each
cluster, providing a 12-month period. Since the interven-
tion is applied at the health centre level, within-cluster
correlation has been accounted for in the sample size
calculation. Observations will be made on individuals
(number of penicillin injections, as documented rou-
tinely by the RHD Register, before, during and after the
intervention), so the effect of the intervention will be
assessed on a within-client basis. Within the randomised
trial design, mixed-methods evaluation will take place to
address the study objectives.
Study setting
The study is set in Australia’s NT (population: 243,700;
population density 0.17/km2), with a high proportion of
remote-dwelling Aboriginal people, for whom English is
often a second language. Each community of adequate
size has one health centre (clinic), the sole provider of
health care for the community. Towns each have one
Aboriginal Health Service but additional mainstream
medical services are also available. There are over 80 in-
dividual Aboriginal communities with health centres in
the NT; health centres are either community-controlled
or operated by the local Government Department of
Health. The NT is divided into two jurisdictions −Top
End (which includes the regional capital) and Centre,
with separate clinic-level governance and separate RHD
Control Programmes.
Inclusion criteria
Communities are eligible to participate if they have at
least 10 individuals with ARF/RHD requiring secondary
prophylaxis, are willing to participate, and provide writ-
ten informed consent. We will seek sites representative
of the NT as a whole including Top End and Central
sites, community-controlled and government run, small
and large, remote and regional.
Individuals from within consenting sites (health centre
staff and ARF/RHD clients), and additional stakeholders
or relevant experts, are enrolled for semi-structured in-
terviews, to address the qualitative study objectives. Indi-
viduals are eligible if they meet criteria for the required
interviewee type, and provide written informed consent.
Consent process
Consent from health centres to participate in the study
requires a signed partnership agreement between the health
centre manager (government-run centres) or management
board (community-controlled centres), and a study investi-
gator. Discussions leading up to the signing of the agree-
ment comprise various stakeholder meetings (e.g. with the
organisation of Remote Medical Practitioners and with the
Table 2 Characteristics of the ‘Improving Secondary Prophylaxis’
stepped-wedge trial
Term/Trial characteristic Definition
Unit Aboriginal health centres
Cluster Pairs of health centres
Individuals People with ARF/RHD who require secondary
prophylaxis with penicillin, whose primary
health centre is enrolled in the study
Timing of start of
exposure
Groups of individuals (all individuals managed
by a given community clinic) are first exposed
at one of a number of discrete time points
Duration of exposure Fixed length: 15 months per clinic
Measurement Repeated measurements from individuals:
record of every penicillin injection received,
as documented in the ARF/RHD Register
Duration of trial 3.5 years
Number of clinics per
cluster
2
Total number of clusters 5
Pre-roll out period 11 to 25 months
Roll out period 15 months
Post-rollout period 3 to 15 months
ARF acute rheumatic fever, RHD rheumatic heart disease
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body overseeing community controlled centres), plus
teleconferences and visits to clinics by research staff,
and provision of detailed materials to health centre staff
and relevant community organisations, to assist them
in deciding on participation or not. Consenting health
centres are able to withdraw consent at any stage without
prejudice. Consent from individuals for their anonymised
RHD Register data to be used to calculate primary and
secondary outcome measures is not sought. The ethics
committee agreed that over-arching consent at clinic/
community level is appropriate.
Consent from individuals to participate in interviews
is sought by project officers using written and verbal
materials, with verbal information in an Australian In-
digenous language where appropriate. For individuals
aged under 15 years, consent is sought from a parent/
guardian, and verbal assent from the interviewee. The eth-
ics committee agreed that for individuals aged 15 years or
older, participation in an interview about their medical
condition and treatment, without parental consent, was
appropriate. All written documentation is de-identified.
Implementation and project phases
The intervention comprises a set of activities developed
and implemented by health centres, aligned under the
six themes of the CCM. An additional file shows in
detail the types of activities which health centres may
adopt (see Additional file 1: Table S1). Implementation
is supported by research staff, and progress is monitored
using CQI processes. This includes 3-monthly adherence
rate reports, presented using simple, coloured graphics
and written summaries. Action plans are amended where
necessary in response to these reports.
The first (now completed) phase of the project com-
prised community engagement for recruitment of con-
senting health centres. The main intervention phases
then comprise: (1) Baseline data collection and planning
(3 months); (2) Intensive implementation phase (15 months);
(3) Maintenance implementation phase (up to 15 months
depending on site’s start date) (Fig. 1). In accordance with
stepped-wedge trial design, the intervention is implemented
at the level of the community/health centre, but measured
by its impact on individuals, i.e. clients with ARF/RHD
(primary endpoint) and health centre staff (secondary
endpoints) [29].
During the 3-month baseline phase, project team
members visit the health centre for two approximately
5-day visits, one for data collection; the second for plan-
ning. Qualitative data including barriers to delivery of
secondary prophylaxis at the health centre are identified
and recorded through workshops facilitated by the project
officer, and an action plan is developed. All site visits,
meetings and other arrangements are planned in collabor-
ation with the community stakeholders and health centre
staff to mimimise the impact on routine service delivery.
At commencement of the 15-month intensive phase,
items in the action plan start being implemented, accord-
ing to clinic priorities. Potential activities for inclusion in
the action plan are listed in Table 3. While necessarily be-
ing tailored to local situations, we aim for homogeneity of
approaches to ensure similarity of the intervention across
sites; this is aided by aligning activities under the six
themes of the CCM. All efforts are made to ensure that
the exposure to (‘dose’ of) the intervention is uniform
across clusters: the duration of intensive phase is identical
for each cluster, and the number of scheduled site visits or
of episodes of telephone support provided by project
staff is uniform. In supporting implementation of the
intervention, the research team work closely with health
centre staff, CQI facilitators and the NT RHD Control
Programme. The action plan is implemented by the health
centre staff, supported by the project team. A project team
Fig. 1 Study design demonstrating the stepped-wedge process. The stepped-wedge design involves the sequential roll-out of an intervention
over periods of time; by study completion, all participating health centres will have received the intervention, for a 15-month period
Ralph et al. Trials  (2016) 17:51 Page 5 of 12
member visits the community monthly, for 1 to 3 days per
trip. Visits are supplemented with email and telephone
contact.
During the maintenance phase, following 15 months of
intensive implementation, the intention is for the clinic’s
agreed action plan to be sustained. One project team
member visits quarterly and email/telephone contact is
made monthly.
A quarterly study newsletter (electronic and paper for-
mat) is circulated to participating sites, investigators and
other interested parties, to promote enthusiasm for the
project, provide cross-fertilisation of ideas between par-
ticipating sites to include in activity plans, congratulate
sites on their progress and share news of any relevant
developments in ARF/RHD management.
This project is specifically designed with sustainability
and transferability in mind, deliverable within existing
health care structures and resources.
Outcome measures
The primary outcome measure is proportion of clients
receiving ≥80 % of their scheduled benzathine penicillin
G injections over the 12-month intervention period,
compared with the pre-intervention period. This will be
calculated using routinely-collected RHD Register data.
Data will be anonymised prior to analysis. All outcome
measures are shown in Table 4.
Sample size
Using a stepped-wedge design with a 3-month period
for each step, with enough communities to provide at
least 30 subjects at each step, and taking into account
within-cluster correlation, we calculated that 300 clients
will provide 90 % power and a two-sided significance
level of 5 % to detect an increase from 20 % of subjects
receiving ≥80 % of their scheduled penicillin injections
to 40 %. This number of clients will provide more than
Table 3 Potential activities for inclusion in health centre’s action items, grouped under the six streams of the Chronic Care Model
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Table 4 Trial outcome measures
Primary outcome • Proportion of clients receiving 80 % or more of their scheduled benzathine penicillin G (BPG) injections over the
12-month intervention period, compared with the pre-intervention period
Secondary outcomes • The proportion of scheduled injections that a client receives in a 12-month period
• The average number of days at risk. ‘Days at risk’ is the number of days over 28 days between scheduled injections
in a month. For clients on 3-weekly injections, ‘Days at risk’ is the number of days over 21 days between scheduled injections
• Proportion of clients receiving at least 90 % of scheduled BPG injections over a minimum 12-month period
• Proportion of clients receiving 50–79 % and <50 % of scheduled BPG injections over a minimum 12 month period
• Recurrence rate and proportion of ARF episodes that are recurrences, compared to non-participating communities and
to the whole jurisdiction
• Impact of the intervention on RHD clients’ experience of care including their perception and understanding of the disease
and its management
• Improvement in delivery of other services for RHD clients
• Effect of the programme on delivery of other routine services
ARF acute rheumatic fever, RHD rheumatic heart disease
Ralph et al. Trials  (2016) 17:51 Page 6 of 12
90 % power to detect a doubling of the rate, if the pre-
intervention rate is higher than 20 %. We estimated that
health centres at up to 12 communities would be required
to ensure a minimum of 300 clients diagnosed with ARF/
RHD requiring secondary prophylaxis with penicillin.
The sample size is conservative (i.e. potentially larger
than required) as it was calculated based on estimated
between-client differences rather than within-client dif-
ferences, which are usually smaller. That is, since change
within a person is what is being measured, and within-
client differences (variability within a person) are usually
less than between-client differences (variability between
people), and lower variance is associated with a lower re-
quired sample size, this study will, therefore, be well-
powered. We have chosen an ambitious target (doubling
the proportion of clients receiving 80 % or more of their
scheduled injections) because a complex intervention
such as this needs to show a substantial, clinically mean-
ingful benefit if it is to be more widely recommended.
The ratio of female to male ARF/RHD clients is approxi-
mately 1.3 to 1. Randomisation will be by community, so
all ARF/RHD clients requiring secondary prophylaxis in
each community will automatically be included.
Randomisation
Clusters comprise pairs of health centres, entering the
study at 3-monthly steps in random order. The random
allocation code was generated by the statistician investi-
gator (AK), using StataCorp 2015 Stata Statistical Soft-
ware: Release 14 (StataCorp LP, College Station, TX,
USA). The pairing of health centres was chosen prior to
randomisation on grounds of geographical proximity to
facilitate travel and minimise project costs, given the
very large distances involved. The investigators and the
health centres will be informed of the next two centres
to commence after the previous centres have been enrolled,
to maximise allocation concealment, but also permit
adequate time for logistical planning.
This design ensures that all health centres will receive
the potential benefits of the intervention while using a ro-
bust design (randomisation to intervention timing), and
maximising efficiency (study personnel can provide inten-
sive support for different health centres sequentially) [30].
Data
Data sources chiefly include the NT RHD Register for
quantitative analyses, and semi-structured interviews and
project officer reports for qualitative analyses. Both
provider and client perspectives will be sought, although
as the intervention chiefly seeks to change health systems,
there will be a particular focus on health provider perspec-
tives. These plus the range of other data sources are listed
in Table 5. Important variables included in the RHD
Register which will be extracted include client sex, age,
date and place of receipt of each penicillin injection during
the study period and occurrence of any ARF episodes
during the study period.
Statistical methods plan for measuring outcomes
Most analyses will be undertaken using generalised linear
mixed models. As the outcomes for clients within a
community are not independent of each other, the
method of analysis will take this correlation into account.
The primary outcome is binary so will be analysed using
this approach with a logit link. This analysis will allow a
comparison of the effect in each community. Outcomes
that are normally distributed will be analysed using
the mixed-model approach to account for the within-
community correlations.
For outcomes that can be measured accurately in shorter
(1–3 month) time periods, trends over time can be assessed
within these mixed-model approaches.
Any outcomes that are measured at a community level
will be analysed using either a McNemar’s test for binary
outcomes or a paired t test for normally distributed
continuous outcomes. These analyses can be extended
to incorporate the effect of covariates if necessary.
Secondary analyses will include models to assess client
or community factors that are related to outcomes. Sta-
tistically significance will be understood to be attained
when the p value is <0.05.
Evaluation plan for measuring objectives
The evaluation framework is based on recommended
strategies for evaluating complex interventions [31–33].
It seeks to answer the overall question of whether the
intervention works, as well as the ‘hows’ and ‘whys’ of
success or failure [31, 34]. The evaluation is based on a
conceptual framework called programme theory [34–36].
The programme theory for this study (Fig. 2) is a systematic
configuration of ‘prescriptive assumptions’ of the project
(what action is required to improve adherence to ARF/
RHD secondary prophylaxis?) and ‘descriptive assumptions’
(why will adherence be affected by these actions?). The
CCM provides the scaffold to stipulate the cause-and-effect
sequence through which actions affect outcomes [37].
The successes of three domains will be tested (Fig. 3):
implementation success (that the intervention was ap-
propriately implemented); action theory success (that
the intervention has successfully affected the causal vari-
able in the conceptual theory); and conceptual theory
success (that the intervention has successfully affected
the causal variable and that the outcome variable has
been successfully affected).
Evaluation measures will be based on research objectives
(Table 5) under the categories of efficiency, effectiveness,
impact, relevance and sustainability, as well as measures to
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examine implementation process, fidelity and performance.
Efficiency measures will answer: ‘To what extent did health
centres change their delivery of ARF/RHD care to align
with the systems-based intervention?’ Effectiveness
measures will answer: ‘To what degree did adopting
the systems-based intervention improve processes of
ARF/RHD care and adherence to secondary prophylaxis’
and ‘Which elements of the intervention were most effect-
ive in activating change?’ Impact and relevance measures
will answer: ‘Did the intervention, a model of care designed
to optimise health systems, improve overall adherence to
secondary prophylaxis for ARF/RHD and minimise ‘days at
risk’?’ Sustainability measures will answer: ‘Which of the
activities and streams of the CCM were sustained during
maintenance phase?’ Process and fidelity will be measured
by asking: ‘What was the acceptability and completeness
of implementation of the intervention package, and of
individual items (measured from the health centre and
client perspective)?’, ‘What were the barriers and en-
ablers of implementation?’, ‘What were the barriers and
enablers of organisational change?’ Performance will be
measured by asking: ‘What were the factors associated
with success in achieving organisational and client-level
improvements in secondary prophylaxis for ARF/RHD?’
Answers to these questions will allow us to answer the
question as to whether outcomes arise as a result of the
intervention and what elements of the intervention
contribute to its success or failure.
Table 5 Sources of data for addressing research objectives
Research objective Data collection tools Frequency
1. To test whether a model of care
designed to optimise health systems
improves adherence to secondary
prophylaxis for RHD
• RHD Register data
• Spreadsheet of time on intervention for
each community
• Continuous
2. To assess the extent to which health
clinics change their delivery of RHD care to
align with the systems-based model and
the barriers and enablers of organisational
change
• Systems Assessment Tool (SAT), a component
of the One21seventy tool RHD Continuous
Quality Improvement package
• Project Officer Reports – structured reports from
project staff detailing implementation
• Baseline and post intensive phases
• Completed at every site visit
• Semi-structured interviews with clients/carers
of clients, clinic managers, RHD coordinators,
RHD programme staff, other relevant staff (chronic
disease coordinators, NT Health Development
public health nurses), using an interview guide for
each group of participants
• Mostly baseline and post intensive phases
• Project Officer Reports • Completed at every site visit
• Document review (e.g. meeting minutes, feedback
reports from CQI audits)
• As arise
3. To explore the degree to which adopting
the systems-based model improves processes
of RHD care and adherence to secondary
prophylaxis and which elements of the model
are most effective in activating change
• RHD SAT and RHD Register • Baseline and post intensive phases
• Semi-structured interviews as described above • Clients/carers: baseline and post intensive phases
• Clinic staff and Control Programme staff: baseline
and post intensive phases
• Other relevant stakeholders: baseline and post
intensive phases
• Project Officer Reports • Completed at every site visit
4. To explore environmental, organisational
and team factors associated with success in
achieving organisational and patient-level
improvements in secondary prophylaxis for
RHD
• RHD SAT and RHD Register • Baseline and post intensive phases
• Semi-structured interviews as described above • Mostly baseline and post intensive phases
• Project Officer Report • Completed at every site visit
• Document review (e.g. meeting minutes, feedback
reports from CQI audits)
• As arise
5. To assess the impact of the systems-
based model on other services for RHD
clients
• RHD CQI audit of ARF/RHD clinical measures, a
component of the One21seventy tool RHD
Continuous Quality Improvement package
• Baseline and post intensive phases
6. To assess the impact of the systems-
based model on other routine services
delivered in the clinics
• NT Aboriginal health key performance indicators data • Baseline and post intensive phases
7. To assess the impact of the intervention
on clients’ experience of health care in
relation to their ARF/RHD
• Interview guide for RHD clients • Baseline and post intensive phases
ARF acute rheumatic fever, CQI continuous quality improvement NT Northern territories, RHD rheumatic heart disease
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Fig. 2 (See legend on next page.)
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The analysis approach for qualitative data collected
throughout the phases of the trial, including interviews
and project officer reports, will be confirmatory (hypoth-
esis-driven) [38]. An analytical framework will organise
the data once it has been coded and analysed using
thematic analysis. Data will be managed using Nvivo
software (version 10, QSR International Pty. Ltd, Doncaster,
VIC, Australia).
Ethics
The study has received ethical approval from the Human
Research Ethics Committee of the NT Department of
Health and Menzies School of Health Research (approval
number 2012–1756), and the Central Australian Human
Research Ethics Committee (approval number 2013–126).
Trial registration details are: Australian New Zealand
Clinical Trials Registry: ACTRN12613000223730.
Discussion
This will be the first randomised trial internationally to
test a model of care to improve delivery of secondary
prophylaxis for ARF and RHD. RHD is responsible for
an unacceptably high burden of premature morbidity and
mortality in Indigenous Australians, and disadvantaged
populations globally [3]. Improved secondary prevention
would make a major contribution to reducing this disease
burden. This study is occurring within a coordinated body
of work seeking to develop for the first time a compre-
hensive, evidence- based strategy for ending RHD [39].
Feasibility of the study is facilitated by the broad expertise
of the investigator team, spanning clinical practice, quanti-
tative research, statistical methods, qualitative methods,
health services research and evaluation.
Community engagement and recruitment of consent-
ing health centres took place during 2012 and 2013. The
required sample size of ARF/RHD clients on secondary
(See figure on previous page.)
Fig. 2 Programme theory. The programme theory (or project strategy) uses the six themes of the Chronic Care Model (health system, delivery
system design, decision support, clinical information systems, self-management support and community supports) as the scaffold for activities to
implement within the study intervention. A cascade of potential outcomes arising from these activities is shown, ultimately leading to increased
adherence and thence, reduction in acute rheumatic fever recurrence rates
Fig. 3 Evaluation framework. The central panel of this summarised schematic of the theory-driven evaluation framework illustrates the interplay
between implementation (delivery of the intervention to clients, intervention (the agents of change that affect determinants), determinants
(change mechanisms) and outcomes (improved adherence). Underpinning theories shown in the right hand panel are action theory (the intervention’s
power to affect determinants), and conceptual theory (the determinant’s ability to affect outcomes). External moderators to be accounted for
(the environment, organisation factors and team factors) are shown in the left hand panel
Ralph et al. Trials  (2016) 17:51 Page 10 of 12
prophylaxis was exceeded after enrolment of 10 sites; in
fact the number of total clients at study commencement
within the first 10 sites to consent was 408 (minimum
sample size = 300); hence, the study should be well-
powered to determine any difference in the primary out-
come measure. A broad representation of community
sizes, locations and governance structures exists within
the 10 participating communities.
Methodological challenges encountered during imple-
mentation of this study to date have arisen related to the
stepped-wedge design, the type of ‘treatment’ to which
clinics are randomised, and from the study environment.
Time lags are an important challenge to address in
stepped-wedge designs. We have observed that the time
lag between intensive phase start date at a given site and
when the intervention may plausibly start having meas-
urable effects, not just on clinic processes but also on
patients, is likely to be variable from site to site. We also
recognise that clinics may struggle to develop and enact
their action plan in accordance with study timelines and
may, therefore, need to adjust subsequent study milestones
at given sites accordingly.
A specific challenge and potential limitation for a trial
in which the ‘treatment’ is an intervention package is
that of fidelity − the degree to which the intervention is
delivered as intended. Substantial efforts have been made
to achieve homogeneity of the intervention across sites,
including the components as devised and delivered at in-
dividual clinics, and the ‘dose’ (amount of support received
by the project officers). However, there are inevitable vari-
ations, and we acknowledge that careful documentation of
fidelity and dose are required to ensure that results will be
interpretable regarding associations between intervention
components and outcomes. However, such a challenge
should not prevent complex interventions being subjected
to rigorous study designs such as clinical trials.
Patient movements comprise another challenge. Abo-
riginal people frequently spend time in two or more
communities. The RHD Register nominates one clinic
as a person’s primary clinic (where the majority of their
injections are administered) and secondary clinic(s) are
also recorded. In documenting patient movements (new
diagnoses, deaths, people moving from one site to another
such that their primary clinic is reassigned), preliminary
findings suggest a substantial number of movements are
occurring. Such movements in and out of the cohort will
need to be taken account of in analyses.
Characteristics of the study sites include very high staff
turnover at health centres, and frequent disruption of
clinic activities due to other priorities in communities,
in particular funerals, which may result in closure of the
clinic for some days in respect of ceremonial activities.
We have found additional challenges in creating a metric
for the measurement of staff turnover, and also in creating
a metric for community remoteness or disadvantage.
Health centre staff are busy with clinical commitments
and complex acute care management, and there is the po-
tential for them to suffer research fatigue due to the high
number of studies being conducted at their sites. We are
aware of this potential issue and have sought to demon-
strate how this study can be directly beneficial to enrolled
sites, and to be flexible in our approach; however, flexibil-
ity can pose a threat to intervention fidelity.
Improving the delivery of secondary prophylaxis is the
major priority in ARF/RHD control in Australia and glo-
bally to reduce deaths and suffering from RHD. The
model we are trialling is designed to fit within current
structures of health service delivery, and to require min-
imal additional resources. The study design is rigorous,
the primary endpoint (proportion who receive ≥80 % of
injections) is of clinical importance for individual clients,
and the evaluation will also allow us to determine the
broader benefits of the intervention, along with any
shortcomings. If successful, there is a high likelihood of
the model being adapted into routine service delivery;
the study investigators are well-aligned with policy-
makers able to promote uptake of the research findings.
Success in improving adherence in this study may also
have important relevance to adherence to medications
for other chronic diseases − leading causes of the large
difference in life expectancy between Australia’s Indigen-
ous and non-Indigenous populations. It will also provide
guidance for improved RHD care internationally.
Trial status
This trial is underway. Ongoing recruitment of partici-
pants for interviews and ongoing project officer site visits
are in progress.
Additional file
Additional file 1: Table S1. Suggested activities for each theme of the
Chronic Care Model. This table provides a detailed description of the
types of activities which participating health centres may adopt, in order
to improve delivery of secondary prophylaxis for rheumatic fever/rheumatic
heart disease. The suggested activities are categorised according to which
theme of the chronic care model they best relate to. (DOCX 23 kb)
Abbreviations
ARF: acute rheumatic fever; BPG: benzathine penicillin G; CQI: continuous
quality improvement; DOH: Department of Health; NT: Northern Territory
(Australia); RHD: rheumatic heart disease.
Competing interests
The authors have no conflicts of interest.
Authors’ contributions
Designed the study: JRC, RSB, VJ, BJC, GPM, KE and AK; participated in study
implementation: JLdD, KB, AM, APR and VJ; developed the evaluation
framework: CR and VJ; wrote the first draft of the manuscript: APR. All
authors have read and approved the final manuscript.
Ralph et al. Trials  (2016) 17:51 Page 11 of 12
Acknowledgements
We thank the associate investigators of the study: Associate Professor Alex
Brown, Ms Marea Fittock, Dr Christine Connors, Dr Rosalie Schultz, Associate
Professor Suzanne Belton and Ms Amanda Lingwood for contributing to
methodological development, and Ms Amy Parry for major contributions to
an early version of the study protocol. This study is funded by the Australian
National Health and Medical Research Council (1027040).
Author details
1Menzies School of Health Research, Darwin, NT, Australia. 2Telethon Kids
Institute, University of Western Australia, and Princess Margaret Hospital for
Children, Perth, WA, Australia. 3Charles Darwin University, Darwin, NT,
Australia. 4Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
5Paediatric Department, Royal Darwin Hospital, Darwin, NT, Australia.
6National Health and Medical Research Council Clinical Trials Centre,
University of Sydney, Sydney, NSW, Australia.
Received: 12 October 2015 Accepted: 11 January 2016
References
1. Australian Institute of Health and Welfare. Cardiovascular disease: Australian
facts. Cardiovascular disease series. Cat. no. CVD 53. Canberra: AIHW. 2011.
http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418530.
Accessed 20 Jan 2016
2. RHDAustralia (ARF/RHD writing group). The Australian guideline for
prevention, diagnosis and management of acute rheumatic fever and
rheumatic heart disease (2nd ed). National Heart Foundation of Australia
and the Cardiac Society of Australia and New Zealand. 2012. http://www.
rhdaustralia.org.au/sites/default/files/guideline_0.pdf. Accessed 20 Jan 2016
3. Ralph AP, Carapetis JR. Group A streptococcal diseases and their global
burden. Curr Top Microbiol Immunol. 2013;368:1–27.
4. RHD Australia. iPhone and Android apps. 2015. http://www.rhdaustralia.org.
au/apps. Accessed 20 Jan 2016
5. Lawrence JG, Carapetis JR, Griffiths K, Edwards K, Condon JR. Acute rheumatic
fever and rheumatic heart disease: incidence and progression in the Northern
Territory of Australia 1997–2010. Circulation. 2013;128(5):492–501.
6. Michaud C, Rammohan R, Narula J. Cost-effectiveness analysis of
intervention strategies for reduction of the burden of rheumatic heart
disease. In: Narula JVR, Reddy KS, Tandon R, editors. Rheumatic fever.
Washington, D.C: American Registry of Pathology; 1999.
7. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic
fever. Cochrane Database Syst Rev. 2002;3:CD002227.
8. Padmavati S, Sharma KB, Jayaram O. Epidemiology and prophylaxis of rheumatic
fever in Delhi− a five year follow-up. Singapore Med J. 1973;14:457–61.
9. WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart
Disease. Rheumatic fever and rheumatic heart disease: report of a WHO
Expert Consultation, Geneva, 29 October −1 November 2001. WHO
Technical Report Series 923. Geneva: World Health Organization; 2004.
10. McDonald M, Brown A, Noonan JR, Carapetis J. Preventing recurrent rheumatic
fever: the role of register based programmes. Heart. 2005;91:1131–3.
11. Ralph AP, Fittock M, Schultz R, Thompson D, Dowden M, Clemens T, et al.
Improvement in rheumatic fever and rheumatic heart disease management
and prevention using a health centre-based continuous quality improvement
approach. BMC Health Services Res. 2013;13:525. doi: 10.1186/1472-6963-13-
525.
12. Humphery K, Weeramanthri T, Fitz J. Forgetting compliance: Aboriginal health
and medical culture. Darwin: Northern Territory University Press in association
with the Cooperative Research Centre for Aboriginal and Tropical Health; 2001.
13. World Health Organization. Adherence to long-term therapies: evidence
for action. Noncommunicable diseases and mental health adherence to
long-term therapies project. Geneva: World Health Organization; 2003.
14. Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J. Challenging perceptions of
non-compliance with rheumatic fever prophylaxis in a remote Aboriginal
community. Med J Aust. 2006;184:514–7.
15. Mincham CM, Toussaint S, Mak DB, Plant AJ. Patient views on the
management of rheumatic fever and rheumatic heart disease in the
Kimberley: a qualitative study. Aust J Rural Health. 2003;11:260–5.
16. Davidson PM, Abbott P, Davison J, Digiacomo M. Improving medication uptake
in Aboriginal and Torres Strait Islander peoples. Heart Lung Circ. 2010;19:372–7.
17. Hoy WE, Kondalsamy-Chennakesavan SN, Nicol JL. Clinical outcomes
associated with changes in a chronic disease treatment program in an
Australian Aboriginal community. Med J Aust. 2005;183(6):305–9.
18. Su J-Y, Skov S. An assessment of the effectiveness of the Tiwi Sexual Health
Program 2002–2005. Aust N Z J Public Health. 2008;32(6):554–8.
19. Haynes RB, Ackloo E, Sahota N. Interventions for enhancing medication
adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
20. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving
chronic illness care: translating evidence into action. Health Aff. 2001;20:64–78.
21. Northern Territory Government Department of Health. The Northern
Territory chronic conditions self management framework 2012–2020.
Darwin. 2012. http://digitallibrary.health.nt.gov.au/prodjspui/bitstream/
10137/551/5/CCSM2012-2020.pdf. Accessed 20 Jan 2016
22. Bailie RS, Si D, O'Donoghue L, Dowden M. Indigenous health: effective and
sustainable health services through continuous quality improvement. Med J
Aust. 2007;186:525–7.
23. Bailie R, Si D, Dowden M, O'Donoghue L, Connors C, Robinson G, et al.
Improving organisational systems for diabetes care in Australian Indigenous
communities. BMC Health Serv Res. 2007;7:67.
24. Gordis L. Effectiveness of comprehensive-care programs in preventing
rheumatic fever. N Engl J Med. 1973;289:331–5.
25. Bach JF, Chalons S, Forier E, Elana G, Jouanelle J, Kayemba S, et al. 10-year
educational programme aimed at rheumatic fever in two French Caribbean
islands. Lancet. 1996;347:644–8.
26. Nordet P, Lopez R, Duenas A, Sarmiento L. Prevention and control of
rheumatic fever and rheumatic heart disease: the Cuban experience
(1986-1996-2002). Cardiovasc J Afr. 2008;19:135–40.
27. One21seventy National Centre for Quality Improvement in Indigenous
Primary Health Care website. http://www.one21seventy.org.au/. Accessed 20
Jan 2016
28. Burgess CP, Sinclair G, Ramjan M, Coffey PJ, Connors CM, Katekar LV.
Strengthening cardiovascular disease prevention in remote indigenous
communities in Australia’s Northern Territory. Heart Lung Circ. 2015;24(5):450–7.
doi:10.1016/j.hlc.2014.11.008.
29. Copas AJ, Lewis JJ, Thompson JA, Davey C, Baio G, Hargreaves JR.
Designing a stepped wedge trial: three main designs, carry-over effects and
randomisation approaches. Trials. 2015;16:352.
30. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review.
BMC Med Res Methodol. 2006;6:54.
31. Oakley A, Strange V, Bonell C, Allen E, Stephenson J, RIPPLE Study Team.
Process evaluation in randomised controlled trials of complex interventions.
BMJ. 2006;332:413–6.
32. Wolff N. Randomised trials of socially complex interventions: promise or
peril? J Health Serv Res Policy. 2001;6:123–6.
33. Hawe P, Shiell A, Riley T. Complex interventions: how ‘out of control’ can a
randomised controlled trial be? BMJ. 2004;328:1561–3.
34. Chen H-T. Theory-driven evaluation: conceptual framework, application and
advancement. In: Strobl RLO, Heitmeyer W, editors. Evaluation von
Programmen und Projekten für eine demokratische Kultur. Wiesbaden:
Springer; 2012. p. 17–40.
35. Sharpe G. A review of program theory and theory-based evaluations.
American International J Contemp Res. 2011;3:72–5.
36. Coryn CLS, Noakes LA, Westine CD, Schröter DC. A systematic review
of theory-driven evaluation practice from 1990 to 2009. Am J Eval.
2011;32:199–226.
37. Donaldson SI, Lipsey MW. Roles for theory in contemporary evaluation
practice: developing practical knowledge. In: Shaw IF, Greene JC, Mark MM,
editors. The SAGE handbook of evaluation: policies, programs, and practices.
London: Sage; 2006. p. 56–75.
38. Guest G, MacQueen K, Namey EI. Introduction to applied thematic analysis,
applied thematic analysis. http://www.sagepub.com/sites/default/files/
upm-binaries/44134_1.pdf. 2012. Sage Publications Inc. Accessed 20 Jan
2016
39. Carapetis JR. END RHD CRE (Centre for Research Excellence). 2015.
http://www.rhdaustralia.org.au/research. Accessed 20 Jan 2016
Ralph et al. Trials  (2016) 17:51 Page 12 of 12
